Hepatitis C Prevalence Estimates
HepVu launched interactive maps and updates to state profiles showing state-level estimates of people living with Hepatitis C across the U.S. from 2013 to 2016 – illustrating where communities have been hit hardest by the disease.
Three new state-level maps were launched to visualize opioid prescription rate (2017), narcotic overdose mortality rate (2013-2016), and pain reliever misuse prevalence (2015-2016), highlighting the infectious disease consequences of the opioid epidemic.
Deeper Look: Opioids
Our Deeper Look: Opioids page introduced this year examines the opioid crisis as one of the greatest public health challenges facing the U.S., which has caused an unprecedented surge in drug overdose deaths and fueled the rapid rise in new Hepatitis C infections from injection drug use.
New Advisory Committee Members
The AIDSVu and HepVu Advisory Committee was honored to welcome new members joining its distinguished group of national HIV and viral hepatitis experts to guide the Vu platforms’ strategic direction. Among our new members are Dr. Judith Feinberg and Michael Ninburg, two leading viral hepatitis experts.
Judith Feinberg, MD, Professor, Behavioral Medicine & Psychiatry, WVU School of Medicine
Dr. Feinberg is a Professor of Medicine/Infectious Diseases and a Professor of Behavioral Medicine and Psychiatry at West Virginia University. She also serves as the E.B. Flink Vice Chair of Medicine for Research. Dr. Feinberg has also long been involved in various public health aspects of HIV/AIDS, including resource allocation, policy development, the FDA approval process, and the development of harm reduction programs to prevent the spread of HIV and hepatitis due to the current opioid epidemic.Learn More
Michael Ninburg, Executive Director, Hepatitis Education Project
Michael Ninburg is the Executive Director of the Hepatitis Education Project (HEP), a U.S.-based non-governmental organization dedicated to supporting hepatitis patients. HEP works with patients, clinicians, and policymakers and provides direct services and advocacy for some of the community’s most underserved and marginalized populations, including prisoners and people who use drugs. Michael works with global partners on issues related to hepatitis testing, treatment access, and the development of more efficient hepatitis drugs and diagnostics.Learn More
Insights from HepVu Q&As
We continued to expand on HepVu’s series of Q&A blogs, speaking with nearly a dozen viral hepatitis and opioid experts.
Vu Q&A: Monica Graybeal on Ending Hep C in Washington State
Dr. Monica Graybeal, PharmD, a Hepatitis C ambulatory and community pharmacist at Yakima Valley Farm Workers Clinic, discusses Hepatitis C elimination efforts in Washington State and the need to improve access to Hepatitis C treatment for at-risk communities.Learn More
Vu Q&A: Dr. John Ward on Global Hepatitis Elimination
Dr. John Ward, the Director of the Coalition for Global Hepatitis Elimination, discusses his work with The Coalition for Global Hepatitis Elimination and strategies the organization uses to help prevent viral hepatitis outbreaks.Learn More
Vu Q&A: Guillermo Chacón on Hepatitis among Hispanics/Latinx
Guillermo Chacón, President of the Latino Commission on AIDS, discusses how the Commission raises awareness of the impact of viral hepatitis on the Latinx community and the need for services and programs to address health inequities and a lack of inclusivity in HIV and viral hepatitis care.Learn More
Vu Q&A: Michelle Rose on Perinatal Hepatitis C Transmission in Kentucky
Michelle Rose, MBA, Population Health Manager for Norton Healthcare in Kentucky, explains how testing pregnant women for Hepatitis C throughout the state is helping to reduce perinatal transmission of the virus.Learn More
Vu Q&A: The Opioid Epidemic’s Impact on Hepatitis C in the U.S.
Heather Bradley, PhD, Assistant Professor of Epidemiology at Georgia State University, and Dr. Ron Valdiserri, MPH, Professor of Epidemiology at Emory University, discuss how the opioid epidemic is fueling a rise of new Hepatitis C infections in younger Americans.Learn More